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Rho GTPases have been implicated in diverse
cellular functions and are potential therapeutic
targets. By virtual screening, we have identified a
Rho-specific inhibitor, Rhosin. Rhosin contains two
aromatic rings tethered by a linker, and it binds to
the surface area sandwiching Trp58 of RhoA with
a submicromolar Kd and effectively inhibits GEF-
catalyzed RhoA activation. In cells, Rhosin specifi-
cally inhibited RhoA activity and RhoA-mediated
cellular function without affecting Cdc42 or Rac1
signaling activities. By suppressing RhoA or RhoC
activity, Rhosin could inhibit mammary sphere
formation by breast cancer cells, suppress invasion
of mammary epithelial cells, and induce neurite
outgrowth of PC12 cells in synergy with NGF. Thus,
the rational designed RhoA subfamily-specific small
molecule inhibitor is useful for studying the physio-
logical and pathologic roles of Rho GTPase.
INTRODUCTION
Rho family GTPases are critical intracellular signaling molecules
that regulate cytoskeleton organization, gene expression, cell
cycle progression, cell motility, and other cellular processes
(Etienne-Manneville and Hall, 2002; Ridley, 2001; Zohn et al.,
1998). Abnormal Rho GTPase activities have been implicated
in multiple human pathologies (Sahai and Marshall, 2002; Boett-
ner and Van Aelst, 2002). RhoA and the closely related RhoC, in
particular, are involved in cancer progression and metastasis.
Upregulation of RhoA and/or RhoC activities have been reported
in several human cancers (Bellizzi et al., 2008; Faried et al., 2007;
Horiuchi et al., 2003). RhoA or RhoC deficiency suppresses the
invasiveness of breast cancer cells (Pille´ et al., 2005; Chan
et al., 2010), whereas elevated RhoA and/or RhoC activity can
induce breast cancer cell migration, invasion, and metastasis
(Brantley-Sieders et al., 2008; Joshi et al., 2008). The RhoA/
RhoC subfamily of Rho GTPases has been suggested to serve
as potential therapeutic targets.
RhoA subfamily GTPases cycle between the GTP-bound,
active and the GDP-bound, inactive states in response to aChemistry & Biology 19,variety of upstream signals, including growth factors, cytokines,
adhesion molecules, and cell intrinsic oncogenic cues. These
incoming signals activate guanine nucleotide exchange factors
(GEFs) that in turn activate Rho GTPases to elicit cellular
responses. Within the Rho GTPase signaling module, several
strategies of intervention have been proposed for effective
suppression of Rho GTPase activities (Marchioni and Zheng,
2009; Vigil et al., 2010). Among them, targeting the GEF-Rho
GTPase interactive surface essential for the guanine nucleotide
exchange reaction has been successfully applied to the rational
design of a lead Rac GTPse inhibitor, NSC23766, that specifi-
cally binds to the surface groove of Rac1 involved in GEF
interaction and effectively inhibits Rac1 activity in diverse phys-
iological and pathological systems (Gao et al., 2004). To date,
however, despite extensive efforts devoted to the development
of inhibitors targeting RhoA/RhoC (Genth et al., 2008; Narumiya
et al., 2000; Evelyn et al., 2010), successful identification of
useful small molecules that work specifically on the RhoA
subfamily Rho GTPases has not been reported. Issues related
to efficiency, specificity, and/or drug ability have been a
hindrance.
In the current work, we used a structure-based rational design
strategy coupled with in silica and protein binding screening to
identify a lead Rho-specific inhibitor, Rhosin. Rhosin contains
two aromatic chemical fragments tethered by a properly spaced
linker, enabling it to bind to two adjacent shallow grooves
on the RhoA surface required for GEF interaction with submicro-
molar affinity. Rhosin specifically inhibits GEF activation of
RhoA in vitro and in cells and can potently suppress breast
cancer cell proliferation and invasion and induce neurite
outgrowth in PC12 cells. It is useful for studying the physiological
function of RhoA subfamily GTPases and for determining the
therapeutic potential of Rho targeting in pathologic conditions.
RESULTS
Rational Targeting of the GEF-RhoA Interactive
Surfaces
Based on a high-resolution crystal structure of Rac1-Tiam1
complex, we successfully identified a chemical compound,
NSC23766, that specifically binds to the surface groove of
Rac1 required for interaction with GEFs and effectively inhibits
Rac1 activity in diverse physiological and pathological systems
(Gao et al., 2004; Akbar et al., 2006). Extensive structural studies699–710, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 699
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et al., 2005) led us to hypothesize that small molecules bound
to the surface sites of RhoA GTPase involved in recognition by
its GEFs could similarly inhibit RhoA activity and consequent
downstream signaling. We used protein:protein interaction
data from published X-ray crystal structures of the RhoA-LARG
complex (PDB ID 1X86) (Kristelly et al., 2004) and virtual
screening to search for small molecules that bind to a surface
region of RhoA surrounding Trp58 that would predictably inter-
fere with association with LARG (Figure 1A). Trp58 situates at
the center of the LARG binding site of RhoA, as revealed in the
LARG-RhoA co-crystal structure. Figure 1A shows a partial
grid of the virtual screening targeting site, and depicts Trp58 at
the position between two shallow pockets of RhoA surface
involved in LARG recognition. From the docking of more than
four million compounds from the ZINC library (International
Zinc Association, Washington, DC), the top scoring (Krieger
et al., 2004) 49 chemicals were tested for their ability to inhibit
the interaction between RhoA and the DH-PH domain module
of LARG in a complex formation assay. Purified LARG, which
specifically binds to RhoA but not Cdc42 or Rac1 (Fukuhara
et al., 2000), was incubated with RhoA in the presence of each
individual compound. Among the chemicals tested, G04 was
capable of suppressing LARG binding to RhoA (Figure 1B; Table
S1 available online). The inhibitory activity of G04 on RhoA/LARG
interaction is dose-dependent with an effective concentration
around 10 to 30 mM under the pull-down assay conditions (Fig-
ure 1B). Possible impurity and degradation of G04 and other
compounds ware tested by amass spec analysis, which showed
no significant degradation product present (Figures 1C and S1
for representative MS data). G04 is specific to the interaction
between RhoA and its GEFs including LARG, DBL, LBC, p115
RhoGEF, or PDZ RhoGEF and does not interfere with the binding
of Cdc42 or Rac1 to their respective GEFs (Figures 1D and 1E),
nor the interaction between RhoA and its effector/GAP/GDI
ROCK, mDia, PKN, Rhoteckin, p190RhoGAP, or RhoGDI (Fig-
ure S1). An examination of the structural analogs of G04 sug-
gested that those compounds that contain the quinoxaline and
indole/benzimidazole rings sharing a linker of sufficient length
and flexibility retained the inhibitory activities (Table S2),
whereas two analogs, A01 and A08, each containing only one
aromatic head of G04, did not bind to RhoA (Figure S1). These
results are consistent with the possibility that the tethered
aromatic ring structures with proper linker length and flexibility
are important for the effective binding to RhoA.
The Lead Inhibitor G04 Specifically Binds to RhoA
to Inhibit GEF Reaction of RhoA
The unique Trp58 residue at the GEF recognition site of RhoA
allowed us to use its intrinsic fluorescence to monitor the direct
interaction of G04 with RhoA. Titration of increasing concentra-
tions of G04 readily quenched the tryptophan fluorescence
emission of RhoA dose-dependently, whereas an analog of
G04, A03, was not effective (Figure S2), suggesting a binding
of G04 to RhoA that affects Trp58 fluorescence. To more
strictly quantify the direct binding interaction between RhoA
and G04, a microscale thermophoresis analysis (Duhr and
Braun, 2006) was carried out using purified RhoA protein. This
assay shows that G04 specifically binds to WT RhoA with an700 Chemistry & Biology 19, 699–710, June 22, 2012 ª2012 Elsevieraffinity of 0.4 uM Kd (Kd = 354 ± 48 nM; Figure 2A), whereas
it does not detectably interact with Cdc42 or Rac1, nor the
GEF, LARG (Figures 2A and S2). As positive controls, Cdc42
and Rac1 were found to interact with their inhibitors CASIN
and NSC23766, respectively, in similar assays (data not shown).
To further confirm the structural motif of RhoA involved in G04
binding, RhoA point mutants bearing Ala mutations around
the predicted G04 binding site, i.e., K7A, Q63A and L69A, were
examined for their binding affinity to G04 by thermophoresis
analysis. G04 showed significantly reduced affinity toward
L69A (Kd = 10502 ± 2310 nM), K7A (Kd = 2909 ± 1030 nM),
and Q63A (Kd = 3471 ± 912 nM; Figure 2B), indicating that
these residues participate in the G04 binding. We also have
analyzed the interaction between G04 and the RhoAW58A
mutant by an affinity binding assay and found that mutation of
Trp58 of RhoA to alanine partially inhibits G04 binding, yielding
a Kd of 6.2 mM compared with G04 binding to WT RhoA with a
Kd of 0.4 mM (Figure 2C). These data, together with the
Trp fluorescence assay of G04 titration to WT RhoA protein
(Figure S3), strongly suggest that G04 interaction with RhoA
involves Trp58 and/or the surrounding region. To examine
whether G04 could specifically inhibit GEF-catalyzed guanine
nucleotide exchange of RhoA, a GDP/GTP exchange assay
was performed in the presence of increasing concentrations of
G04. G04 was able to inhibit the nucleotide exchange of RhoA
catalyzed by LARG dose-dependently (Figure 2D) but was inac-
tive in affecting Cdc42 and Rac1 exchange catalyzed by their
selective GEFs, intersectin and TrioN, respectively (data not
shown). Consistent with the significantly reduced G04 binding
activity, although L69A still retained the WT activity to respond
to LARG in the GEF reaction, it has lost responsiveness to G04
inhibition at the GEF assay conditions (Figure 2E). Collectively,
these results indicate that G04 binds to RhoA with micromolar
affinity at the predicted docking pocket involved in GEF
recognition.
The Lead Inhibitor G04 Specifically Inhibits RhoA
Subfamily Rho GTPases in Cells
To examine whether G04 is effective in specifically suppressing
RhoA activity in cells, NIH 3T3 cells grown in serum-free media
were treated with G04 in different concentrations, followed by
stimulation with or without 10% calf serum. As shown in Fig-
ure 3A, G04 strongly inhibited RhoA-GTP formation in both
serum-free and serum stimulation conditions with an EC50
10–30 mM under the assay conditions, but did not affect the
activities of endogenous Cdc42 and Rac1 in the same cells. To
evaluate the ability of G04 to inhibit RhoA-mediated cell func-
tions, we next examined actin cytoskeleton structures of cells
stimulated by serum or LPA in the absence or presence of
G04. Figures 3B and S3 show that in the presence of 30 mM
G04, both stress fiber and focal complex formation of the cells
were significantly reduced, whereas the lamellipodia and filapo-
dia stimulated by PDGF and bradykinin, respectively, were not
affected. To examine whether G04 may act reversibly, we
washed the G04-treated cells and then analyzed the effects on
actin polymerization and focal adhesion complex at 6 hr and
24 hr time points. The results showed that removal of G04
by the wash could reverse the inhibitory effects of G04 (Fig-
ure 3B). In addition, G04 significantly inhibited integrin-mediatedLtd All rights reserved
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Figure 1. Identification of G04 as an Inhibitor of RhoA-LARG Interaction
(A) A simulated dockingmodel of G04 onRhoA surface. (Upper) Top view of the binding pocket of RhoA bound toG04. (Lower) Top view of the predicted structural
contacts of G04 in the binding pocket around Trp58 of RhoA.
(B, upper) The inhibitory effect of a panel of compounds predicted by virtual screening on RhoA interaction with LARG DH-PH module was tested in a complex
formation assay. (His)6-tagged LARG (1 mg) was incubated with GST alone or GST-RhoA (1 mg) immobilized on glutathione agarose beads in the presence or
absence of the1mM indicated compounds. After an incubation at 4C for 1 hr, the beads associated with (His)6-LARGwere detected by anti-His western blotting.
(B, lower) Dose-dependent specific inhibition of LARG binding to RhoA by G04. (His)6-tagged LARG (1 mg) was incubated with GST alone or GST-fused RhoA on
glutathione agarose beads in a binding buffer containing different concentrations of G04. The beads associated with (His)6-LARG were detected by anti-His
western blotting.
(C) G04 in DMSO solution was dissolved intomethanol at 1:100 ratio. Fifty microliters of themethanol solution is dissolved into 450 ml of 1:1 water:acetonitrile with
0.1% formic acid. The prepared compound solution was processed by Thermo Scientific LTQ-FT hybridmass spectrometer consisting of a linear ion trap used for
tandem mass spectrometry and a Fourier transform ion cyclotron resonance mass spectrometer.
(D) The inhibitory effects of G04 on the interaction between RhoA and multiple Rho GEFs. NIH 3T3 cells stably overexpressing GST-DBL, Flag-LBC or transiently
overexpressing GFP-p115 RhoGEF or Flag-PDZRhoGEF, were harvested and the cell lysates were subjected to the His-RhoA or GST-RhoA pull-down assay in
the absence or presence of G04 at the indicated concentrations.
(E) G04 does not affect Rac1 or Cdc42 binding to respective GEFs. Purified, immobilized GST-Rac1 or GST-intersectin were incubated with cell lysates ex-
pressing myc-Tiam1, (His)6-TrioN or (His)6-Cdc42 in the presence or absence of indicated concentrations of G04. The co-precipitates were subject to western
blotting to detect Rac1 binding to Tiam1 or triN, and cdc42 binding to intersectin.
See also Figure S1 and Tables S1 and S2.
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Rational Design of Small Molecules Targeting RhoAcell adhesion to fibronectin (Figure S3). Under these assay
conditions, G04 did not appear to be cytotoxic as it did not affect
the survival status of the cells at the concentrations that showChemistry & Biology 19,efficacy in disrupting actin stress fiber and focal adhesions (Fig-
ure S3). Given the implicated role of Rho activity in actin cyto-
skeleton organization and adhesion (Hall, 1998), these results699–710, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 701
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Figure 2. Biochemical Characterizations of G04 Interaction with RhoA
(A–C)Microscale thermophoresis analysis of G04 to RhoA. Purified RhoA, Cdc42, Rac1, or RhoAmutants were first labeled with Alexa-647 fluorescence dye. G04
was titrated between 4 and 100,000 nM or 0.76 and 250,000 nM to a constant amount of labeled RhoA, RhoA mutants, Cdc42, or Rac1 proteins (100 nM). The
reaction was performed in 50 mMHEPES, 50 mMNaCl, 0.01% Tween20 and 2 mMMgCl2. The samples were incubated at room temperature for 1 hr before the
measurements. Data were normalized to either DFnorm [&] (10*(Fnorm(bound)  Fnorm (unbound))) or Fraction bound (DFnorm [&]/amplitude).The average Kd
values ± SD were calculated from three replicates. All the data are representative of three independent experiments. Error bars represent SD.
(D) G04 was effective in inhibiting RhoA GDP/GTP exchange stimulated by LARG in a dose-dependent manner. Fifty nanomolar (50 nM) RhoA loaded with
BODIPY FL-GDP was incubated at 25C in an exchange buffer containing 100 mMNaCl, 5 mMMgCl2, 50 mM Tris$HCl (pH 7.6), and 0.5 mMGTP in the absence
(top line) or presence of 30 nM LARG. Increasing concentrations of G04 were included in the exchange buffer as indicated.
(E) Examination of the binding residues of G04 on RhoA through the GDP/GTP exchange assays of RhoAmutants. (Left) The GDP/GTP exchange activities of WT
RhoA and RhoAmutants K7A, Q63A, and L69A were examined in the presence of LARG. The relative GDP dissociation of each mutant at 10 min was normalized
to that of WT RhoA without LARG in a parallel reaction. (Right) The inhibitory effects of G04 (10 mM) on the GDP/GTP exchange activities of WT RhoA and the
respective RhoAmutants were examined. The GEF reaction conditions were similar to that in (D). The relative inhibitory effects by G04 were normalized to that of
WT RhoA.
See also Figure S2.
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mediated cellular events.
To further define the cellular specificity of G04, we next
examined its effect on the closely related RhoB and RhoC
proteins of the RhoA subfamily and downstream signaling.
Consistent with its mode of action, G04 inhibited RhoB and702 Chemistry & Biology 19, 699–710, June 22, 2012 ª2012 ElsevierRhoC activities in cells similarly to that of RhoA (Figure S3),
since these RhoA subfamily members share identical surface
residues required for G04 binding. G04 efficiently inhibited
serum-induced phosphor-MLC formation, an event mediated
by the RhoA effector ROCK, without affecting p-PAK level that
is regulated by Rac/Cdc42 (Figure 3C). We compared the effectLtd All rights reserved
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Figure 3. Cellular Validation of G04 as a Specific Inhibitor of RhoA Activity
(A) NIH 3T3 cells were treated with G04 at the indicated concentrations for 24 hr in serum-freemedia. Cells were subsequently stimulatedwith or without 10%calf
serum for 15 min and were subjected to GST-Rhotekin or GST-PAK1 effector domain pull-down assays, and the activities of RhoA, Cdc42, and Rac1 were
examined. Blotting of the respective total cell lysates was carried out in parallel. Relative amounts of GTP-bound form of the GTPases were quantified by
densitometry measurements and normalized to those of the unstimulated cells.
(B) Effect of G04 on cell stress fiber and focal complex assembly. NIH 3T3 cells were treated with or without 30 mM G04 in serum-free media for 24 hr, and
subsequently were stimulated with 10% calf serum for 15 min. Medium containing G04 was removed and cells were washed for 3 times. The cells were then
fixed 6 and 24 hr after the wash, respectively, and stained with Rhodamine-phalloidin for F-actin and anti-vinculin for focal adhesion complexes. Images shown
are representative of more than 100 cells examined.
(C) G04 treatment affects signaling downstream of RhoA, but not that of Rac1/Cdc42. Western blots are of p-PAK and p-MLC and relevant controls of NIH 3T3
cells treated with G04 at indicated concentrations in serum-free media and subsequently stimulated by 10% calf serum for 10 min.
(D) A comparison of G04 and ROCK inhibitor, Y-27632. The relevant control NIH 3T3 cells or cells treated with G04 or Y-27632 of indicated concentrations were
stimulated with 10% calf serum for 10 min prior to blotting for p-MLC.
See also Figure S3.
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Rational Design of Small Molecules Targeting RhoAof G04 with the ROCK inhibitor, Y27632, and found that G04 and
Y27632 had a similar effect in inhibiting MLC phosphorylation
(Figure 3D).
To examine whether G04 works specifically through the
RhoA-mediated pathway, we performed mutant rescue ex-
periments using constitutively active RhoA or ROCKII mutant
and a G04 binding defective RhoA mutant, RhoAL69A. G04Chemistry & Biology 19,treatment did not alter actin stress fiber and focal adhesion
complex formation induced by a constitutively active ROCKII
or RhoA mutant, nor the constitutively active RhoA mutant-
induced downstream signaling to p-MLC and p-FAK (Figures
4A and S4). Furthermore, the RhoA mutant, RhoAL69A,
defective in G04 binding but not GEF activation (Figures 2B
and 2E), was resistant to G04 in cells by maintaining unaffected699–710, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 703
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Figure 4. Cellular Validation of G04 Speci-
ficity by Ectopic Expression of RhoA
Mutants or RhoGEFs
(A) WT NIH 3T3 cells and RhoAQ63L expressing
cells were grown on tissue culture dish. After
a 24 hr starvation in the presence of 30 mM G04,
cells were stimulated with 10% calf serum and
were co-stained with Rhodamine-phalloidin for
F-actin.
(B) NIHT3 cells were transduced with retrovirus
expressing EGFP-RhoAL69A mutant. Cells were
then treated with G04 at indicated concentrations
in serum-free medium. Cells were subsequently
stimulated with 10% calf serum for 15 min and
were subjected to GST-Rhotekin effector domain
pull-down assay. The RhoA-GTP and EGFP-
RhoAL69A-GTP levels were examined by RhoA
and EGFP antibodies, respectively. Blotting of the
respective total cell lysates was carried out in
parallel. Relative amounts of the GTP-bound form
of the GTPases were quantified by densitometry
measurements and normalized to those of the
unstimulated cells.
(C) NIH 3T3 cells stably expressing DBL or Vav
were treated with G04 at the indicated concen-
trations for 24 hr in serum-free medium. Cells were
subsequently stimulated with or without 10% calf
serum for 15 min and subjected to GST-Rhotekin
or GST-PAK1 effector domain pull-down assay,
and the activities of RhoA, Cdc42, and Rac1 were
determined. Blotting of the respective total cell
lysates was carried out in parallel. Relative
amounts of the GTP-bound form of the GTPases
were quantified by densitometry measurements
and normalized to those of the unstimulated cells.
See also Figure S4.
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was responsive to G04 inhibition (Figure 4B). Together, the
RhoAL69A, RhoAQ63L, and active ROCKII rescue experiments
suggest that G04 can specifically suppress RhoA activity and
RhoA-mediated signaling function. Finally, DBL and Vav are
two GEFs that can activate a broad spectrum of Rho GTPases
including RhoA, Cdc42 and Rac1. We found that G04 could
readily inhibited RhoA-GTP formation, but not that of Cdc42 or
Rac1, in serum-starved DBL- or Vav-expressing cells, further
supporting the specificity of G04 toward RhoA (Figure 4C).
Based on these in vitro and cellular properties, we termed G04
a Rho activity specific inhibitor, or Rhosin.
Rhosin Effectively Reverses the Functions of Breast
Cancer Cells and Neuronal Cells Regulated by RhoA
Elevated RhoA and RhoC activities have been associated with
cancer cell hyperproliferative and invasive behaviors (Sahai
and Marshall, 2002; van Golen et al., 2000; Clark et al., 2000).
Next, we investigated the effect of Rhosin on the mammosphere
formation of breast cancer MCF7 cells, a property associated704 Chemistry & Biology 19, 699–710, June 22, 2012 ª2012 Elsevier Ltd All rights reservedwith their tumorigenic potential. Rhosin
showed a dose-dependent inhibition of
endogenous RhoA activity (Figure 5A)
and cell growth of MCF7 cells (Figure 5B).To assess the cellular effect of Rhosin, we performed cell
apoptosis assay and cell cycle analysis. As shown in Figure S5,
Rhosin could significantly induce cell apoptosis but did not
affect cell cycle progression. These results suggest that a partial
inhibition of RhoA activity may not affect cytokinesis as that
shown by a complete removal of RhoA gene by gene targeting
(Melendez et al., 2011). Moreover, Rhosin dose-dependently
reduced RhoA and p-MLC1 activities of MCF7 cell-derived
mammospheres with an EC50 30–50 mM, and caused
decreased size and reduced number of mammospheres in
MCF7 cells (Figures 5C and 5D). Interestingly, Rhosin has no
effect on the non-tumorigenic epithelial MCF10A cells derived
mammosphere growth (Figure 5D). These results indicate that
Rhosin is effective in targeting RhoA-mediated breast cancer
cell proliferation.
Both RhoA and its closely related subfamily member, RhoC,
have been implicated in promoting breast cancer cell migra-
tion, invasion and metastasis (Pille´ et al., 2005; Chan et al.,
2010; Brantley-Sieders et al., 2008). We next examined the
effect of Rhosin on breast cancer cell migration and invasion
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Figure 5. Rhosin Inhibits RhoA Activity and Suppresses Proliferation of Breast Cancer Cells
(A) Rhosin inhibits RhoA activity in MCF7 cells. MCF7 cells were treated with G04 or Analog3 of indicated concentrations for 24 hr in a serum-free media. Cells
were subsequently stimulated with 10% fetal bovine serum for 15 min and were subjected to Rhotekin effector domain pull-down assays, and the activities of
RhoAwere determined. Blotting of the respective total cell lysates was carried out in parallel. Results shown are representative of three independent experiments.
(B) Rhosin inhibits MCF7 cell growth. MCF7 cells were plated at 1.53 104 /24 well in the presence of G04. Cell numbers were determined at the indicated times.
Error bars represent SD.
(C) Rhosin inhibits RhoA and its downstream signaling activities in MCF7-derived mammospheres. MCF-7 cells were dissociated to single cells with trypsin and
cultured for 10 days at the density of 2 3 104/ml in suspension. The spheres were collected and subjected to GST-Rhotekin effector domain pull-down assays,
and the activities of RhoA were examined. Blotting of the respective total cell lysates was carried out in parallel. Relative amounts of GTP-bound form of RhoA
were quantified by densitometry measurements and normalized to those of the untreated cells. Lower: Western blots are p-MLC of MCF7-derived spheres
treated with G04 at indicated concentrations.
(D) Rhosin inhibits MCF-7 cell-derived mammosphere formation. MCF7 and MCF10A cells were dissociated to single cells with trypsin and cultured in the media
with G04 at the indicated concentrations for 10–14 days at the density of 23 104/ml in suspension. Photos were taken after 10–14 days of culture. Images shown
are representative of five to ten fields containing a total of at least 100 spheres that were chosen randomly. The average size of mammary sphere were measured
and calculated relative to the control.
See also Figure S5.
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Rational Design of Small Molecules Targeting RhoAproperties. The results showed that Rhosin potently inhibited
MCF7 cell migration and invasion activities, dose-dependently
(Figures 6A and 6B). In human mammary epithelial cells that
were endowed with a highly invasive phenotype by RhoC
expression (van Golen et al., 2000), Rhosin readily inhibited
RhoC-GTP formation and the resulting invasive activity (FiguresChemistry & Biology 19,6C and 6D). These results indicate that Rhosin can suppress
RhoA and RhoC mediated breast cancer cell migration and
invasion.
Inactivation of RhoA promotes the neurite outgrowth of
neuronal cells (Sebo¨k et al., 1999; Kozma et al., 1997). Next,
we tested the effect of Rhosin on the neuritogenesis of a well699–710, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 705
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Figure 6. Rhosin Suppresses the Migration and Invasion of Breast Cancer Cells
(A) Rhosin inhibits MCF7 cell migration. MCF7 cells were subjected migration assays in the presence of G04. The percentages of the cells that migrated toward
a 10%FBSgradient for 16 hr in a transwell migration chamber were calculated by dividing the number ofmigrated cells into the number of input equivalents plated
on the transwell and then normalized by cell proliferation. Error bars represent SD.
(B) Rhosin inhibits MCF7 cells invasion. The invasive activities were assayed in a Matrigel-coated transwell. The MCF7 cells that succeeded in invasion into the
Matrigel were stained with 5%Giemsa solution for visualization and quantification 16 hr after plating in the presence of G04 of the indicated concentrations. Error
bars represent SD.
(C and D) Rhosin supresses HME-RhoC cells invasion activity via inhibiting the RhoC activity. HME cells and RhoC expressing HME cells were grown in Ham’s
F-12 medium supplemented with 5% FBS, insulin, hydrocortisone, epidermal growth factor, and cholera toxin. (C) The invasive activities were assayed in
aMatrigel-coated transwell. The cells that succeeded in invasion into theMatrigel were stained with 5%Giemsa solution for visualization and quantification 16 hr
after plating in the presence of G04 of the indicated concentrations. Error bars represent SD. (D) The cells were treated with 30 mM for 24 hr in serum-free media.
Cells were subsequently stimulated with 10% fetal bovine serum for 15 min and were subjected to a pull-down assay, and the activity of RhoC was determined.
Blotting of the respective total cell lysates was carried out in parallel. Results shown are representative of three independent experiments.
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Rational Design of Small Molecules Targeting RhoAcharacterized neuronal cell line, PC-12. In the presence of
50 mg/ml NGF and 30 mM Rhosin, neurite initiation and branch-
ing were significantly increased compared with that following
NGF treatment alone (Figures 7A and 7B). A Rho GTPase activity
pull-down assay confirmed that the RhoA-GTP level of PC12
cells was responsive to Rhosin (Figure 7C). These observations
indicate that Rhosin can induce neurite outgrowth and branch-
ing of PC12 cells similar to that of previously reported C3 toxin
treatment (Sebo¨k et al., 1999).
DISCUSSION
Rho family GTPases belong to the Ras-like small GTPases
superfamily and are intracellular signal transducers involved in
diverse cell signal transduction processes from cell adhesion
molecules, growth factor receptors, G protein coupled recep-
tors, and cytokines. It has become increasingly appreciated
that Rho family members, RhoA and RhoC in particular, are often
upregulated or hyperactivated in human diseases including706 Chemistry & Biology 19, 699–710, June 22, 2012 ª2012 Elseviercancer and inflammation, and these Rho GTPases can serve
as useful targets in reversing pathologic conditions such as
cancer cell proliferation and invasion (Faried et al., 2007; Horiu-
chi et al., 2003). Activation and signal transduction through Rho
GTPase regulated pathways require cascades of protein-protein
interactions, including enzymatic reactions of kinases and
GTPases. However, Rho GTPases, like Ras, are considered un-
druggable by conventional means. This is in part because the
small GTPases themselves are globular structures with limited
surface structural areas suitable for high affinity binding by small
molecules (Kristelly et al., 2004). Thus, extensive efforts have
previously been devoted to the development of inhibitors of
the upstream regulators (e.g., farnesyl or gerynyl transferases
[Sebti and Der, 2003]), Rho GTPases themselves (e.g., by
bacteria toxins [Genth et al., 2008] or small molecules [Gao
et al., 2004; Onesto et al., 2008]) and downstream effectors
(e.g., ROCK and SRF [Narumiya et al., 2000; Evelyn et al.,
2010]), of the GTPase signaling pathways, but none have
achieved clinical utility.Ltd All rights reserved
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Figure 7. Rhosin Induces Neurite Outgrowth of PC12 Cells in Synergy with NGF
(A and B) PC12 cells were treated with 30 mMG04 and 50 ng/ml NGF for 72 hr. Photos were taken at (A) indicated time pointswhen (B) relative neurite lengths per
cell were measured. At least 100 cells were chosen randomly for the measurement. Total neurite output was determined by dividing the combined lengths of all
neurites by the number of neurite-bearing cells.
(C) PC12 cells were treated with G04 of indicated concentrations for 24 hr in serum-free media. Cells were subsequently stimulated with 5% fetal calf serum and
10% horse serum for 15 min and were subjected to effector domain pull-down assays, and the activity of RhoA was examined by GST-Rhoteckin pull-down.
Relative amounts of RhoA-GTP were quantified by densitometry measurements and normalized to those of unstimulated cells.
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Rational Design of Small Molecules Targeting RhoAActivation of Rho GTPases by the DBLl family GEFs is known
to be one major mechanism leading to the activated state of
multiple Rho family members including RhoA, RhoC, Cdc42
and Rac1. Extensive structural and biochemical work has
provided detailed information on how this class of GEFs recog-
nizes a Rho GTPase substrate and catalyzes the GDP/GTP
exchange. The studies have presented a possibility that small
molecules designed for specifically targeting the GEF - Rho
GTPase interaction could be obtained to affect the Rho GTPase
activities, not unlike previously identified brefeldin A that can
bind to and inhibit an ARF small GTPase GEF. Applying this
rationale, we previously identified a lead Rac activation-specific
inhibitor, NSC23766, that displays a micromolar binding affinityChemistry & Biology 19,to Rac1 at the GEF binding site and is active for inhibiting GEF
activation of Rac1 (Gao et al., 2004). However, effort in
enhancing the efficacy of this lead has proven difficult mostly
due to the low affinity nature of the available targeting site on
Rac1.
Here, we have identified a lead small molecule inhibitor that
specifically targets RhoA and closely related RhoB and RhoC
by structure-based rational design. This inhibitor, Rhosin,
contains two aromatic chemical fragments that are tethered by
a properly spaced linker, with each likely bound to a distinct,
shallow groove of RhoA. In vitro it is able to specifically inhibit
the RhoA-GEF interaction and RhoA activation by GEFs. In
cells, Rhosin blocks RhoA activation and RhoA-mediated MLC699–710, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 707
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Rational Design of Small Molecules Targeting RhoAphosphorylation, actin stress fiber formation and focal adhesion
assembly without affecting the activity or signaling events of
endogenous Cdc42 or Rac1. Moreover, this compound showed
no cytotoxicity or nonspecific effect on the constitutively active
RhoA or ROCK mutant-induced actomyosin changes. Finally,
by suppressing RhoA or RhoC activity, Rhosin was active in
decreasing mammosphere formation and inhibiting invasion of
breast cancer cells, and promoting neurite outgrowth from
neuronal cells. Thus, Rhosin constitutes a Rho-specific small
molecule inhibitor that is useful in the study of the physiological
role of Rho and for tackling Rho-mediated pathologies.
Cdc42 or Rac1 shares high homologies with RhoA in the
region between switches I & II involved in Rhosin binding and
GEF interaction. An analysis of the amino acid sequences and
the 3D structure of the RhoA binding pocket indicates that
Cdc42 contains a Phe56 instead of Trp58 in the critical site of
Rhosin binding, whereas Rac1, although containing mostly
conserved amino acid residues, has a minor structural confor-
mation difference from RhoA (Worthylake et al., 2000; Kristelly
et al., 2004). Likely due to similar reasons, the previously charac-
terized Rac inhibitor, NSC23766, shows high specificity toward
Rac1 (Gao et al., 2004). The detailed mode of action by Rhosin
in interaction with RhoA awaits further structural illustrations.
We have performed multiples assays in this study to test the
target binding affinity (i.e., Kd), the IC50 for the inhibition of
GEF-RhoA binding, and the EC50 of cellular activity, of G04. In
the assay conditions, G04 displays a Kd of 0.4 uM to RhoA,
and aweaker efficacy in inhibiting the GEF binding to RhoA reac-
tion or cellular RhoA-GTP formation (at over 10 uM). This is not
unlike most kinase inhibitors that have a high binding affinity to
targets but may require higher concentrations to be effective to
inhibit a kinase-substrate interaction or a kinase reaction in cells.
Although the lead inhibitors of RhoA identified in the current
studies remain a distance from pharmaceutical applications,
our studies put forward a demonstrated example that the GEF
reaction of small GTPase activation is a valid site for rationalized
targeting. The discovery of Rhosin, a lead inhibitor targeting
RhoA that contains two aromatic chemical fragments tethered
by a properly spaced linker, with each likely bound to a distinct,
shallow groove of RhoA, adds to the previously characterized
Rac GTPase-specific small molecule inhibitors that shared the
principle of targeting the GEF recognition site of a Rho GTPase
(Kristelly et al., 2004). It further raises the possibility that design
and search for double-headed, low-affinity binding structures
tethered by a properly sized linker may be applicable to small
GTPases or other difficult to target biological molecules.
SIGNIFICANCE
Small molecule chemicals, as one of the major structural
classes of drugs, are broadly used in targeting oncoproteins
and their signaling pathways (Verdine and Walensky, 2007).
However, only proteins containing deep hydrophobic
pockets are considered druggable (Hopkins and Groom,
2002; Russ and Lampel, 2005), which significantly limits the
scope of small molecule drug development in targeted
therapy. RhoA has a globular structure with limited surface
pocket areas, which is a hinder for high affinity binding
by small molecule compounds. The discovery of Rhosin,708 Chemistry & Biology 19, 699–710, June 22, 2012 ª2012 Elseviera lead inhibitor targeting RhoA that contains two aromatic
chemical fragments tethered by a properly spaced linker,
with each likely bound to a distinct, shallow groove of
RhoA, adds to the previously characterized Rac GTPase-
specific small molecule inhibitors that shared the principle
of targeting the guanine nucleotide exchange factors (GEF)
recognition site of a Rho GTPase. It further raises the
possibility that design and search for low affinity binding
structures tethered by a properly sized linker may be appli-
cable to small GTPases or other difficult to target biological
molecules. Comparing with other inhibitors for RhoA or
RhoA signaling pathway, Rhosin has higher affinity and
specificity without detectable toxicity in normal cells. Our
functional studies in breast cancer cells and neuronal cells
further suggest its potential usage in cancer and neurologic
disorders.
EXPERIMENTAL PROCEDURES
Virtual Screening
The atomic interactions between RhoA and LARG were obtained from PDB ID
1X86 (Krieger et al., 2006). The concave surface to either side RhoA Trp58
meets these criteria and was chosen as the binding site for virtual screening
(see Supplemental Experimental Procedures). The in silico compound library
was derived from the ZINC purchasable (International Zinc Association-
America, Washington, DC) compound set. Single molecules were used to
create conformers using OMEGA at default settings (OpenEye Scientific
Software). The conformer library was screened across the W58 binding site
using FRED, rigid ligand and receptor, default scoring (OpenEye Scientific
Software), in parallel mode on an SGI Altix 4700 computer. The top 1000
hits were submitted for flexible-ligand, rigid-receptor docking and energy
minimization using Molegro, default scoring (Molegro ApS). The top 100
compounds were selected and the top 49 were obtained for testing. Among
the 49 compounds, Y1-Y17 were obtained from ChemBridge (San Diego,
CA); G1-G16 were obtained from InterBioScreen Ltd. (Russia); O1-O12 were
obtained from Enamine (Ukraine); P1-P5 were obtained from ChemDiv (San
Diego, CA). All the analogs of G04 (A01-A16) were obtained from P&G
Compound library (Cincinnati, OH).
In Vitro Complex Formation Assay
About 1 mg of (His)6-tagged LARG DH-PH was incubated with 1 mg of EDTA-
treated (1 mM) GST-fused RhoA or Cdc42 or GST alone in binding buffer
(20 mM Tris$HCl [pH 7.6], 100 mM NaCl, 1% BSA, 1% Triton X-100, 1 mM
MgCl2), and 15 ml of suspended glutathione agarose beads. Compound G04
or other chemicals were added in the incubation buffer at the indicated
concentrations. After incubation at 4C for 1 hr under constant agitation, the
glutathione beads were washed twice with the binding buffer. The amount of
(His)6-tagged protein co-precipitated with the GST-fusion-bound beads was
detected by anti-His western blotting. Similarly, cell lysates containing myc-
Tiam1, (His)6-Cdc42, (His)6- TrioN or (His)6- RhoA were mixed with purified
GST-Rac1, GST-Cdc42, GST-mDia, GST-PKN, GST-Rhotekin, GST-ROCKII,
GST-p190GAP, or GST alone, and the pairwise association between the
proteins was assessed in the presence of the indicated amount of G04 in
the respective assays.
Microscale Thermophoretic Analysis
A NanoTemper Monolith Instrument (NT.015) was used for measuring thermo-
phoresis (see Supplemental Experimental Procedures). In this instrument
an infra red-Laser (IR Laser) beam couples into the path of light (i.e., fluores-
cence excitation and emission) with a dichroic mirror and is focused into
the sample fluid through the same optical element used for fluorescence
imaging. The IR laser is absorbed by the aqueous solution in the capillary
and locally heats the sample with a 1/e2 diameter of 25 mm. Up to 24 mW of
laser power was used to heat the sample without damaging the biomolecules
(Wienken et al., 2010). Thermophoresis of the protein in presence of varyingLtd All rights reserved
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performed at room temperature and standard deviation was calculated
from three independent experiments. Data were normalized to either DFnorm
[&] (10*(Fnorm(bound) - Fnorm (unbound))) or Fraction bound (DFnorm
[&]/amplitude).
Guanine Nucleotide Exchange Assay
A 200 ml solution of Tris-HCl (20 mM, pH 7.6), NaCl (100 mM), and MgCl2
(1 mM) containing purified RhoA (50 nM), Cdc42 (2 mM) or Rac1(2 mM) protein
was incubated with 25 nM of BODIPY FL-GDP (Invitrogen) at 25C until
the monitored fluorescence signal was constant, and then 10 mM GDP was
added. Self-exchange was monitored by reading the change in fluorescence
intensity. The GEF-catalyzed exchange was performed by adding purified
LARG (10 nM), intersectin (10 nM), or TrioN (50 nM) to the BODIPY- FL-
GDP-loaded RhoA, Cdc42, or Rac1 in the presence or absence of G04
(1–120 mM). Fluorescence intensity was measured using a Cary Eclipse fluo-
rescence spectrophotometer (Gao et al., 2004).
Endogenous Rho GTPase Activity Assay
NIH 3T3 cells, MCF7 cells, or human mammary epithelial (HME) cells were
grown in log phase in a 10-cm dish or a six-well dish, and were starved in
serum-free medium in the presence or absence of G04 at indicated concen-
trations for 24 hr and were subsequently stimulated with 10% calf serum or
fetal bovine serum for 15 min. Cells were lysed in a buffer containing 20 mM
Tris-HCl, pH 7.6, 100 mM NaCl, 1% Triton X-100, 10 mM MgCl2, 2 mM NaF,
and protease inhibitors (2 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin).
Lysates were clarified, the protein concentrations were normalized, and the
GTP-bound RhoA, Rac1 or Cdc42 in the lysates were measured by respective
anti-RhoA, Rac1, and Cdc42 western blotting of the effector domain pull-
downs.
Statistical Analysis
All experimental data were analyzed and compared for statistically significant
differences by two-tailed Student’s t test. Data are presented as the aver-
aged values ± standard deviations (SD) where applicable. For microscale
thermophoresis assay, nonlinear regression was used to fit curves to the
mean and SD (n = 3) calculated with GraphPad Prism software. For western
blot quantification, one representative sample of three or more experiments
is shown.
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